Lantheus Holdings, Inc. revenue by segment LNTH

Annual Quarterly

Lantheus Holdings, Inc. splits its revenue into 10 lines in its filings. The largest line in Q3 of fiscal 2026, the quarter ended Sep 30, 2026 was PYLARIFY at $238.9 million, 61% of the total.

USD in millions. The percent under a figure is the change from the same quarter a year earlier.

Line	TTM Sep 30, 2026	Q3 FY2026 Sep 30, 2026	Q2 FY2026 Jun 30, 2026	Q1 FY2026 Mar 31, 2026	Q4 FY2025 Dec 31, 2025	Q3 FY2025 Sep 30, 2025	Q2 FY2025 Jun 30, 2025	Q1 FY2025 Mar 31, 2025	Q4 FY2024 Dec 31, 2024
Revenue	1,562	390	388	377	407	384	378	373	391
PYLARIFY	960 -5.4% share 61.5%	239 share 61.3%	240 -4.1% share 61.9%	241 -6.5% share 63.8%	240 -9.7% share 59.0%	—	251 share 66.3%	258 share 69.1%	266 share 68.0%
Total Precision Diagnostics	—	—	—	—	—	130 share 33.8%	—	—	—
Definity	344 +3.9% share 22.0%	86 +4.8% share 22.0%	88 +5.2% share 22.7%	85 +6.8% share 22.4%	85 -1.0% share 21.0%	82 share 21.3%	84 share 22.2%	79 share 21.2%	86 share 22.0%
Neuraceq	152 share 9.7%	46 share 11.7%	40 share 10.2%	35 share 9.4%	31 share 7.6%	—	—	—	—
SPECT Business	—	—	—	—	—	—	32 share 8.4%	25 share 6.7%	—
Techne Lite	—	—	—	—	21 -16.4% share 5.2%	21 share 5.5%	—	—	25 share 6.4%
Strategic Partnerships And Other	79 +81.4% share 5.1%	20 share 5.1%	20 +71.9% share 5.1%	16 +52.1% share 4.3%	—	—	12 share 3.1%	11 share 2.9%	8 share 2.0%
Licenseand Royalty Revenues	48 +142.2% share 3.0%	12 +57.6% share 3.0%	11 +221.5% share 2.9%	7 +28.0% share 2.0%	17 +479.2% share 4.3%	7 share 1.9%	3 share 0.9%	6 share 1.6%	3 share 0.8%
Other Precision Diagnostics	—	—	—	—	6 -4.0% share 1.5%	6 share 1.7%	—	—	6 share 1.6%
Other Radiopharmaceutical Oncology	—	—	—	—	—	—	—	—	0 share 0.0%

How these figures are calculated

Quarterly columns are single-quarter amounts. When a 10-Q reports only a year-to-date total, as cash flow statements do, the quarter is that total minus the previous quarter's year-to-date total. The fourth quarter is the annual report's full year minus the first nine months. A column marked YTD is a year-to-date total, shown when the earlier report needed for the single quarter is missing. USD in millions. Each group is a separate split of total revenue, so the groups are not added together. Share of revenue is that line divided by total revenue. The first column adds the latest year-to-date segment amount to the last fiscal year and subtracts the year-ago year-to-date amount. More on our methodology.

Company profile

Industry: In Vitro & In Vivo Diagnostic Substances (SIC 2835)
Listed as: LNTH (Nasdaq)
Fiscal year ends: December 31
Incorporated in: DE
Headquarters: Bedford, MA
SEC filer status: Large accelerated filer
SEC CIK: 1521036
Former names: Lantheus MI Holdings, Inc. (until May 23, 2014)

Other In Vitro & In Vivo Diagnostic Substances companies

All 21 In Vitro & In Vivo Diagnostic Substances companies

Source: SEC EDGAR filings. This is company-reported data, not investment advice.